Activity of Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT trial)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511587-93-00

Acronym

REPRINT

Enrollment

Registered

2025-02-12

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Collecting Duct Carcinoma, Medullary Renal cell Carcinoma

Brief summary

The primary Efficacy Endpoint is Objective Response Rate (ORR)

Detailed description

The secondary endpoints of this study are progression-free survival (PFS), overall-survival (OS) and tolerability.

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGENFORTUMAB VEDOTIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary Efficacy Endpoint is Objective Response Rate (ORR)	—

Secondary

Measure	Time frame
The secondary endpoints of this study are progression-free survival (PFS), overall-survival (OS) and tolerability.	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026